Akero Therapeutics, Inc. (FRA:0K4)

Market Cap	3.86B
Revenue (ttm)	n/a
Net Income (ttm)	-249.57M
Shares Out	n/a
EPS (ttm)	-3.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	46.70
Previous Close	46.66
Day's Range	46.70 - 46.70
52-Week Range	21.19 - 55.10
Beta	n/a
RSI	59.65
Earnings Date	Feb 27, 2026

About Akero Therapeutics

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 63
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0K4

Financial Performance

Financial numbers in USD